Table 2. Specificity of the biomarker model for differentiating Fabry disease from other renal, metabolic and cardiovascular diseases.
| Disease | Age | False positive/total N | Specificity (%) |
| ADPKD | 31±8 | 6/78 | 92 |
| diabetic nephropathy | 58±13 | 0/47 | 100 |
| FSGS | 42±23 | 0/27 | 100 |
| heart failure | 68±10 | 1/9 | 89 |
| hypertension | 66±11 | 1/17 | 94 |
| IgA nephropathy | 35±13 | 0/24 | 100 |
| cardiovascular disease | 66±7 | 3/47 | 94 |
| minimal change disease | 42±10 | 0/12 | 100 |
| membranous nephropathy | 54±20 | 0/9 | 100 |
| kidney stones | 56±8 | 0/8 | 100 |
| renal cell carcinoma | 64±11 | 0/42 | 100 |
| bladder cancer | 66±11 | 4/46 | 91 |
| systemic lupus erythematodes | 41±11 | 0/19 | 100 |
| ANCA vasculitis | 67±6 | 0/27 | 100 |
ADPKD, autosomal dominant polycystic kidney disease; FSGS, focal segmental glomerulosclerosis; ANCA, anti-neutrophil cytoplasmic antibodies. Data are mean ± SD, unless otherwise stated.